zonisamide has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Miyoshi, K; Murata, M; Ogawa, N | 1 |
| Arawaka, S; Fukushima, S; Kato, T; Koga, K; Koyama, S; Sasaki, A; Sato, H | 1 |
2 other study(ies) available for zonisamide and alpha-synuclein
| Article | Year |
|---|---|
Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
Topics: alpha-Synuclein; Animals; Antioxidants; Biopterins; Cell-Free System; Cells, Cultured; Cytosol; Dopamine; Isoxazoles; Ketanserin; Lewy Bodies; Melanins; Mice; Neurons; Oxidative Stress; Parkinson Disease; Quinones; Ubiquitin-Protein Ligases; Zonisamide | 2008 |
Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Count; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Isoxazoles; Male; Mice; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Rats; Substantia Nigra; Time Factors; Zonisamide | 2014 |